Trial reportAlcoholism, clinical and experimental research2009
Effects of alcoholism typology on response to naltrexone in the COMBINE study.
Trial report in Alcoholism, clinical and experimental research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Type A/Type B Alcoholism Predicts Differential Response to Topiramate in a Smoking Cessation Trial in Dually Diagnosed Men.Journal of studies on alcohol and drugs · 2017Trial
- An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015Trial
- Predictors of pretreatment commitment to abstinence: results from the COMBINE study.Journal of studies on alcohol and drugs · 2014Trial
- Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.Biological psychiatry · 2012Trial
- A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.Journal of addiction medicineTrial
- Predicting individual treatment response in alcohol use disorders: a reverse translational proof-of-concept study.Translational psychiatry · 2025Article
- A familial subtype of gambling disorder.Journal of behavioral addictions · 2024Article
- Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: An umbrella review.Alcohol, clinical & experimental research · 2024Review
- Alterations in resting-state functional connectivity in substance use disorders and treatment implications.Progress in neuro-psychopharmacology & biological psychiatry · 2019Review
- Cognitive control in alcohol use disorder: deficits and clinical relevance.Reviews in the neurosciences · 2014Review
- Specific and nonspecific effects of naltrexone on goal-directed and habitual models of alcohol seeking and drinking.Alcoholism, clinical and experimental research · 2013Article
- Medications for unhealthy alcohol use: across the spectrum.Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism · 2011Review
- Typologies of alcohol dependence. From Jellinek to genetics and beyond.Neuropsychology review · 2009Review
- Classifying opioid use disorder based on diagnostic criteria items using cluster analysis.Industrial psychiatry journalArticle
- A modified classification tree method for personalized medicine decisions.Statistics and its interfaceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThis study investigated whether subgroups of alcohol-dependent patients responded differently to naltrexone versus placebo in the NIAAA COMBINE study. In particular, the A versus B and the Early Onset versus Late Onset typologies were examined. Relative to Type A alcoholics, Type B alcoholics are characterized by greater severity, earlier onset, stronger family history, more childhood risk factors (e.g., conduct disorder), and greater frequency of comorbid psychiatric and substance use disorders.
methodsCOMBINE study participants were categorized as Type A or Type B using k-means cluster analysis and variables from 5 domains that have been shown to replicate the original Babor typology efficiently. Early Onset was defined as alcohol dependence beginning before age 25. For the planned analyses, the sample was reduced to the 618 participants receiving naltrexone alone or placebo, either with medical management (MM) alone or with MM plus the Combined Behavioral Intervention (CBI). The a priori primary outcome was percent heavy drinking days during treatment in the groups receiving MM without CBI.
resultsAmong those receiving MM without CBI, Type A alcoholics had better drinking outcomes with naltrexone than placebo, whereas medication condition did not influence outcomes significantly in the Type Bs. Age of onset was not significantly related to outcome. For those receiving CBI, no significant effects were found for either typology.
conclusionsIn this sample, the beneficial effects of opioid antagonism were limited to Type A alcoholics receiving treatment in a MM model. Future studies should investigate the relationship between clinically relevant genotypes, phenotypes such as typologies, and treatment response. More work is also needed to develop practical algorithms for phenotypic assignment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.